Document 0803
 DOCN  M9650803
 TI    A novel adjuvant for use with a blood-stage malaria vaccine.
 DT    9605
 AU    de Souza JB; Playfair JH; University College London Medical School,
       Department of; Immunology, UK.
 SO    Vaccine. 1995 Oct;13(14):1316-9. Unique Identifier : AIDSLINE
       MED/96155139
 AB    An effective vaccine delivery system has been developed for vaccination
       against a blood-stage malaria infection in mice. Subcutaneous
       vaccination with a semi-purified asexual blood-stage malaria antigen
       combined with an adjuvant formulation containing squalane, Tween 80 and
       pluronic L121 (AF) protected mice infected with a lethal P. yoelii
       infection against death and greatly reduced the severity and duration of
       parasitaemia. The adjuvant and the route of immunization are both
       clinically acceptable, thereby making this an attractive delivery system
       for a human malaria vaccine. Protective immunity appeared to be
       associated with an enhancement of both Th1 and Th2 subset cytokines.
 DE    Adjuvants, Immunologic/*THERAPEUTIC USE  Animal  Antibodies,
       Protozoan/BIOSYNTHESIS  Antigens, Protozoan/IMMUNOLOGY  CD8-Positive
       T-Lymphocytes/IMMUNOLOGY  Female  Injections, Subcutaneous  Interferon
       Type II/METABOLISM  Interleukin-4/METABOLISM
       Malaria/BLOOD/IMMUNOLOGY/*PREVENTION & CONTROL  Malaria
       Vaccines/*THERAPEUTIC USE  Male  Mice  Mice, Inbred BALB C  Mice, Inbred
       C57BL  Plasmodium yoelii/*IMMUNOLOGY  Saponins/IMMUNOLOGY/THERAPEUTIC
       USE  Spleen/METABOLISM  T-Lymphocytes, Cytotoxic/DRUG EFFECTS/IMMUNOLOGY
       Th1 Cells/IMMUNOLOGY  Th2 Cells/IMMUNOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).